Member Info for Servalan

May I ask a dumb question, as a relatively inexperienced investor in Harbour? Why did they allow the div to get to such a high level (maybe not amongst peers, but it's high) if they carried so much debt? Any really significant reduction in March will see the sp smashed. Many retail will sell, hedge fund shorters will pile in and US banks, instis will take advantage and throw in some punches as well. Am i exaggerating the risk? I just can't see Mr Market seeing it as sensible even though it is. For the record, I'm ok with debt first, div later. Maybe a buying opp but it has taken ages for Harbour to crawl to even this grossly undervalued level.

Positive article in Investors' Chronicle this week. "Time to stop ignoring this cash backed biotech".

Shield is still paying the price for past mistakes but they are moving in the right direction. It's also a relatively illiquid small biotech on AIM so it couldn't be in a worse market really. It takes time to react to updates like this, there won't be many notable analysts covering this regularly, if any. Biotechs are just coming out of a very long period of terrible share performance with many gone to the wall or taken private. I still shudder at the mere mention of Synairgen. Honestly, I'm surprise Shield has survived this far. Its leadership has vastly improved.

My "investment" here is now worth £13. I keep it open for the shame and a reminder of what not to do. It's working a treat. This company is utter and complete garbage. Don't ever touch an Israeli company with a barge pole. Stay well away. They have a reputation for a reason.

"no penetrative"...that's not quite their market. Look at the Rx graph from openprescribing, tell me that's not great progress. May not be huge numbers but it's growing at a faster rate all the same.

So much jam tomorrow promised, for years, that we'll all need ozempic "when" it finally arrives. If the dividends are cut this will be slaughtered.

£150,349 ( Nov-24: £108,185) c. 39% yoy increase

Great update, everything still on track and what do the dumbdumbs do this morning? sell, of course. Thanks for the chance to pick up some cheaper shares before they get bought out!

Just the usual smooth brains who panic and drop every share they own when someone, somewhere else in the world does something completely unrelated to a company providing the best treatment for iron deficiency.

Taking delight in others who have lost money says a lot about your character. Karma has a way of dealing with your type, eventually.

"Up we go" ....Really? because it has done nothing but go down for years. Your relentless pumping will have no effect on the SP. Nobody is going to buy a single share because of what you post here. Ever.

It is absurd how this responds to news at times but it's a biotech on AIM so easily thrown around at will. Any idiots selling on an FDA license extension deserve what they get. If this was listed in the US it would be at least 100 not 10. Once profitability is shown this is likely to be bought out imho.

Great news and what does the SP do? nothing! If this was listed in the US it would be flying pre-market. I hope Shield gets taken over soon, it will never see even fair value as long as it is stuck in the AIM cess pit.

It's AIM, it's Africa, it's a mine. What could possibly go wrong? Never mind, at least the coo is rewarded for their "performance". Certainly is a performance, day in, day out. One of those farces. Noises Off?

So we are back to more messing around by the mystery investor who uses UBS. IR had told me in an email they were going to try and stop this endless in and out. Looks like that hasn't worked.

September Rx for NHS England: $148,048 (£104,192 Sep '24 42% increase)

It's a UK listed biotech. Of course it is written off as a worthless gamble, that is how these things are viewed here. Look at other FDA approved companies, Shield, Angle(CelLbx..whatever) considered as just penny stocks. Get out of the UK completely, that is the only way to achieve anything close to fair value. US main listed biotechs reflect the future, UK always punished for past mistakes. Biotechs in the UK are done.

Winners? are you insane? this stock has been a disaster for shareholders. Ridiculous levels of pumping here. We all know the dilution is coming.

I contacted IR about their trip to LaLaLulu and the reply was that it was the previous leadership's fault and they would lose too much if they cancelled it now. So a lovely little jolly for them (business class all the way of course) and more academic papers no doubt. Meanwhile, we are just months away from insolvency with next to no sales.

It's British, it's a biotech, it's on AIM. There's 3 good reasons why we are languishing at 6.5p. If this was listed anywhere else it would be flying. Once you've held for a long time you'll get used to the constant disappointment in sp performance. Kicking myself i didn't sell at the last spike.